Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer Clinical research trials and Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer. Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "S" Clinical Trials Conditions > Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer

Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer



Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer

For Condition: Breast Cancer
Status: Recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purposes of this study are to determine the safety of ALIMTA and any side effects that might be associated with it, whether ALIMTA can help patients with breast cancer and how much ALIMTA should be given to patients.
Details:
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Be at least 18 years of old. - Have been diagnosed with breast cancer - At least one year disease-free interval after initial treatment. - Have pre-study laboratory tests that are within the requirements of this study. - Be able to visit the doctor's office weekly during the treatment period. Exclusion Criteria: - To be pregnant or breastfeeding. - To be currently taking aspirin or aspirin- like medicine and unable to stop for a few days during each cycle of therapy. - To have received prior chemotherapy for the treatment of metastatic cancer. Patients may have received prior hormonal treatment. - To have another illness that your doctor thinks would make you unable to participate. - To be unable or not willing to take folic acid and vitamin B12.
Total Enrollment: 

Location and Contact Information:

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician *Recruiting*
Wiesbaden,  , 
Germany
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Badalona,  Barcelona, 
Spain
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Leuven,  , 
Belgium
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Malaga,  , 
Spain
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Munich,  , 
Germany
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Tucuman,  , 
Argentina
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Cluj, Cluj Napoca,  , 
Romania
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Cantabria, Santander,  , 
Spain
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. *Recruiting*
S.M. De Tucuman,  Tucuman, 
Argentina
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. *Recruiting*
Newcastle upon Tyne,  Tyne and Wear, 
United Kingdom
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. *Recruiting*
Birmingham,  West Midlands, 
United Kingdom
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Barcelona,  , 
Spain
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Buenos Aires,  , 
Argentina
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Sector 2, Bucuresti,  , 
Romania
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Namur,  , 
Belgium
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. *Recruiting*
Capitol Federal,  Buenos Aires, 
Argentina
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Brussels,  , 
Belgium
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Valencia,  , 
Spain
Recruiting  

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician. *Recruiting*
Madrid,  , 
Spain
Recruiting  


Additional Information:
Study ID Numbers:
  7491; 
Study Start Date: 
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00065533

Other Breast Cancer Studies:
1. Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

2. Epoetin alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

3. Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

4. Docetaxel and Flavopiridol to Treat Breast Cancer

5. Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer

Related Studies:

Other Breast Cancer Clinical Trials
Other Clinical Trials
Other Namur Clinical Trials

Study of two doses of ALIMTA (pemetrexed) as first line chemotherapy for advanced breast cancer

Modify your Search

  Other Breast Cancer Clinical Trials
  Other Clinical Trials
  Other Namur Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103